Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 12 - Studien 111 bis 120 von insgesamt 366
- Rekrutierung läuftA Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T cell-engaging Antibody Targeting CD20 in Subjects with Relapsed or Refractory B-Cell Malignancies (TITANium)Molekulare Marker
- Rekrutierung läuftThe DEFINITIVE Trial: Diagnostic HER2DX-guided treatment for patients with early-stage HER2-positive breast cancerMolekulare Marker
- Rekrutierung läuftDESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer
- Rekrutierung läuftLaparoscopic versus robot-assisted left-sided pancreatectomy for benign and pre-malignant lesions (DIPLOMA-3): an international multicenter patient-blinded randomized controlled trial
- Rekrutierung läuftPhase 3, Randomized, Open-Label Study of Belentamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone Versus Daratumumab, Lenalidomide, and Dexamethasone in Participants with Newly Diagnose Multiple Myeloma who are inelegible for ASCT
- Rekrutierung läuftLenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintance – A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV)
- Rekrutierung läuftA Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab in Combination withDaratumumab, Lenalidomide, and Dexamethasone with or without Bortezomib asInduction Therapy and Teclistamab in Combination with Daratumumab andLenalidomide as Maintenance Therapy in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma
- Rekrutierung läuftMultizentrisches nationales ITP-Register mit begleitender Bioproben-Sammlung
- Rekrutierung läuftMultizentrisches nationales IPT-Register mit begleitender Bioproben-Sammlung
- Rekrutierung läuftMultizentrisches nationales ITP-Register und begleitende Bioproben Sammlung